Journal article
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Abstract
PURPOSE: To assess the ability of circulating tumor DNA (ctDNA)-based testing to identify patients with HER2 (encoded by ERBB2)-positive gastric/gastroesophageal adenocarcinoma (GEA) who progressed on or after trastuzumab-containing treatments were treated with combination therapy of anti-HER2 and anti-PD-1 agents.
METHODS: ctDNA analysis was performed retrospectively using plasma samples collected at study entry from 86 patients participating …
Authors
Catenacci DV; Kang Y-K; Uronis HE; Lee K-W; Ng MC; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS
Journal
Oncology, Vol. 37, No. 4, pp. 176–183
Publisher
MJH Life Sciences
Publication Date
April 12, 2023
DOI
10.46883/2023.25920992
ISSN
0890-9091